Safety: Phase 2 Monotherapy in 2L PDAC at 320 mg QD (n=21)

4

Safety: Phase 2 Monotherapy in 2L PDAC at 320 mg QD (n=21)

Format

JPEG

Source

Immuneering Corporation

Downloads